A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

September 18, 2024

Primary Completion Date

February 14, 2028

Study Completion Date

February 14, 2028

Conditions
B-cell Malignancies
Interventions
DRUG

AZD5492

CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously

Trial Locations (29)

2100

RECRUITING

Research Site, København Ø

3000

RECRUITING

Research Site, Melbourne

6009

RECRUITING

Research Site, Nedlands

10021

RECRUITING

Research Site, New York

10029

RECRUITING

Research Site, New York

20133

RECRUITING

Research Site, Milan

27157

RECRUITING

Research Site, Winston-Salem

28040

RECRUITING

Research Site, Madrid

28203

RECRUITING

Research Site, Charlotte

33604

RECRUITING

Research Site, Pessac

40138

RECRUITING

Research Site, Bologna

77030

RECRUITING

Research Site, Houston

81675

RECRUITING

Research Site, München

89081

RECRUITING

Research Site, Ulm

92093

RECRUITING

Research Site, La Jolla

94805

NOT_YET_RECRUITING

Research Site, Villejuif

97080

RECRUITING

Research Site, Würzburg

98109

RECRUITING

Research Site, Seattle

200025

RECRUITING

Research Site, Shanghai

310003

RECRUITING

Research Site, Hangzhou

02215

WITHDRAWN

Research Site, Boston

07601

RECRUITING

Research Site, Hackensack

T2N 5G2

RECRUITING

Research Site, Calgary

M5G 2M9

RECRUITING

Research Site, Toronto

H3T 1R2

RECRUITING

Research Site, Montreal

104-0045

RECRUITING

Research Site, Chūōku

277-8577

RECRUITING

Research Site, Kashiwa

08035

RECRUITING

Research Site, Barcelona

08908

RECRUITING

Research Site, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY